Form 4: Haemonetics Director Diane Bryant Awarded Restricted Stock Units

Haemonetics Corporation's Director, Diane M. Bryant, was granted 2,693 restricted stock units (RSUs) as part of the company's long-term incentive plan.

Summary

• Diane M. Bryant, a Director of Haemonetics Corp (HAE), was awarded 2,693 shares of common stock in the form of restricted stock units (RSUs).
• The transaction date for this award was July 24, 2025.
• These RSUs were issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• The RSUs are scheduled to vest 100% on the first anniversary of the grant date.
• Each RSU represents a contingent right to receive one share of Haemonetics' common stock upon vesting.
• Following this transaction, Diane M. Bryant beneficially owns 7,126 shares directly.

Sentiment

Score: 6

Explanation: The filing reports a standard equity compensation event for a director, which is generally a neutral to slightly positive signal as it aligns director interests with shareholders. There are no negative or significantly positive unexpected elements.

Positives

• The RSU award aligns the interests of Director Diane M. Bryant with those of shareholders, as the value of the award is tied to the company's stock performance.
• The grant is part of a pre-existing, approved long-term incentive compensation plan, indicating a structured approach to executive and director compensation.

Future Outlook

The awarded restricted stock units are set to vest 100% on the first anniversary of the grant date, indicating a future conversion of these contingent rights into common stock.

Industry Context

This filing represents a routine equity compensation event for a director within the healthcare technology sector, specifically for a company specializing in blood management solutions. Such awards are common practice across industries to incentivize and retain key personnel.

Comparison to Industry Standards

• The granting of restricted stock units to directors is a standard practice in corporate governance across various industries, including healthcare technology, aligning director incentives with long-term shareholder value.
• The vesting schedule of 100% on the first anniversary is a common structure for director equity awards, similar to practices observed at comparable companies like Medtronic (MDT) or Baxter International (BAX) for their non-employee directors, though specific terms can vary.

Corporate Governance

Related Party Transactions

• The transaction involves the issuance of restricted stock units to Diane M. Bryant, a Director of Haemonetics Corp, which constitutes a related party transaction as it is a compensation arrangement between the company and a member of its board.

Stakeholder Impact

• Shareholders: The RSU award aligns the director's financial interests with shareholder value creation, as the value of the award is tied to the company's stock performance.
• Employees: While not directly impacting employees, such compensation practices for leadership can reflect the company's overall approach to talent retention and incentive structures.

Next Steps

• The 2,693 restricted stock units are expected to vest on July 24, 2026, at which point they will convert into shares of Haemonetics common stock.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director and does not contain information that would fundamentally alter the investment thesis for Haemonetics Corp. It is a standard operational disclosure and does not provide new insights into financial performance, strategic shifts, or significant risks that would warrant a change in investment recommendation based solely on this filing.

Keywords

Haemonetics, HAE, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Award, Long-Term Incentive Plan